Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Platinum-Etoposide in ES-SCLC (CANTABRICO)
NCT04712903Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of durvalumab in small cell lung cancer (SCLC), sponsored by AstraZeneca. Primary endpoints: Number of Patients With Adverse Events Grade >= 3 and Number of Patients With Immune-mediated Adverse Events. Started Dec 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04712903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04712903.